Literature DB >> 3138210

Esthesioneuroblastoma: a comparison of two treatment eras.

C A Spaulding1, M S Kranyak, W C Constable, F M Stewart.   

Abstract

This paper is a retrospective review of 30 patients with esthesioneuroblastoma, an uncommon malignancy of the upper nasal cavity, treated at a single institution from 1959 through 1986. Over the period of study, there has been a gradual evolution of treatment policy and technique with the introduction of craniofacial resections and complex field megavoltage radiation, as well as for Stage C disease, the addition of chemotherapy to radiotherapy and surgery. The 25 patients with a 2 year minimum follow-up are divided into 2 groups depending upon treatment era to determine the impact of modern aggressive therapy upon treatment results. Two-year survival for Group I (1959-1975) was 70% as compared with 87% for Group II (1976-85). For Stage C disease, there was a definite improvement in survival in the later era (88% versus 50%), although relapses did not appear to be circumvented. Salvage therapy has an important role in prolonging survival in this disease.

Entities:  

Mesh:

Year:  1988        PMID: 3138210     DOI: 10.1016/0360-3016(88)90298-2

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  15 in total

1.  Olfactory neuroblastoma and neuroendocrine carcinoma of the anterior skull base: treatment results at the m.d. Anderson cancer center.

Authors:  J R Austin; H Cebrun; M M Kershisnik; A K El-Naggar; A S Garden; F Demonte; L E Ginsberg; S M Lippman; H Goepfert
Journal:  Skull Base Surg       Date:  1996

2.  Meta-analysis of outcome in anterior skull base resection for squamous cell and undifferentiated carcinoma.

Authors:  D E Eibling; I P Janecka; C H Snyderman; S P Cass
Journal:  Skull Base Surg       Date:  1993

3.  Retreatment of advanced esthesioneuroblastoma with high-activity I-125 endocurietherapy: a case report.

Authors:  P P Kumar; F P Ogren; R D McComb; E O Jones; G F McCaul
Journal:  J Natl Med Assoc       Date:  1991-08       Impact factor: 1.798

4.  Risk of Delayed Lymph Node Metastasis in Clinically N0 Esthesioneuroblastoma.

Authors:  Justin G Peacock; William S Harmsen; Michael J Link; Jamie J Van Gompel; Caterina Giannini; Kerry D Olsen; Yolanda I Garces; Michelle A Neben Wittich; Daniel J Ma; Sean S Park; Robert L Foote
Journal:  J Neurol Surg B Skull Base       Date:  2016-07-06

5.  Trigeminal sensory loss in orbital disease.

Authors:  J Rootman
Journal:  Br J Ophthalmol       Date:  1994-06       Impact factor: 4.638

6.  Neuro-rhinosurgical treatment of aesthesioneuroblastoma.

Authors:  R Fahlbusch; U Neubauer; M Wigand; M Weidenbecher; G Röckelein; P Thierauf; R Sauer
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

Review 7.  Esthesioneuroblastoma: Multimodal management and review of literature.

Authors:  Ritesh Kumar
Journal:  World J Clin Cases       Date:  2015-09-16       Impact factor: 1.337

8.  [Hyposmia and epistaxis. Esthesioneuroblastoma (olfactory neuroblastoma)].

Authors:  C Plathow; M-A Weber
Journal:  Radiologe       Date:  2004-02       Impact factor: 0.635

Review 9.  Chemotherapy for cranial base tumors.

Authors:  H E Jacob
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 10.  Review of skull base surgery approaches: with special reference to pediatric patients.

Authors:  J D Kennedy; S J Haines
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.